# ADR 517 — Enterprise Biotechnology Bio Investment Intelligence Platform (P217-R)

## Status

Accepted

## Context

P217-Q established bio innovation ecosystem. P217-R defines Bio Investment Intelligence: venture intelligence, scientific funding network, innovation finance, valuation engine and investment digital twin — before Bio Security (P217-S).

## Decision

1. SoR remains `biotechnology` / `CAP-PLT-BIO-001` for investment *intelligence* — never replace Financial Kernel.
2. Fabric: `meos_bio_investment_intelligence_fabric`.
3. API: `/api/v1/biotechnology/bio-investment*`.
4. Six investment layers; venture, funding, finance intelligence, valuation, KG, and twin platforms.
5. All inference via P214-Z ACL only — `no_module_local_llm`.
6. Human investment oversight and financial transparency controls mandatory; never unverified investment recommendation.
7. Twins via P217-G; manufacturing via P217-L; regulatory via P217-N; marketplace via P217-P; innovation via P217-Q; robotics via P216-Z; quantum via P215-Z.
8. Never replace Core, AI, Quantum, Robotics, Financial Kernel, hospital EMR, LIMS, pharmacy, prior P217 fabrics including Bio Innovation.
9. Foundation for P217-S.

## Consequences

Positive: governed capital intelligence layer for bio-security and future-evolution phases.  
Negative: valuation / portfolio catalogs must stay aligned as autonomous capital systems deepen.

## Alternatives rejected

- Sibling `bio_investment` BC owning Financial Kernel or Core capabilities.
- Module-local LLM or recommending investments without human oversight.
- Merging peer SoRs (EMR/LIMS/pharmacy/Financial Kernel) into biotechnology without ACL peers.

## Related

Law: `ENTERPRISE_BIOTECHNOLOGY_BIO_INVESTMENT.md` · Prior: ADR 499–516 · Next: P217-S
